E Fund Biomedicine ETF (03186.HK) Falls 1.46%, Trades at 0.50% Premium

Newtimespace News: As of 10:57 on August 14, E Fund Biomedicine ETF (03186.HK) stood at HKD 14.800, down 1.46%. The ETF opened at HKD 14.810, with the latest net asset value (NAV) at HKD 14.945, a premium of 0.50%, a 52-week high of HKD 16.950, a 52-week low of HKD 12.710, a turnover of approximately HKD 50,300, and assets under management of approximately HKD 25.41 million.

E Fund Biomedicine ETF (03186.HK) tracks the Solactive Biopharma Select Index, selecting biopharma companies listed in Hong Kong and the U.S., covering global innovation hubs and China's growth dividends in one go, including 100 leading names such as Beigene, Innovent Biologics, Akeso, Kelun-Biotech, Junshi Biosciences, Hengrui Medicine, focusing on innovative drugs, CXO, biotech and other cutting-edge sectors. Against the backdrop of the National Essential Drugs List including innovative drugs for the first time, record-high out-licensing deals, and broad-based recovery in CXO orders, the ETF provides investors with a convenient tool to efficiently capture the allocation window of Hong Kong biopharma sentiment recovery and global innovative drug beta resonance.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.